Self-management of immunomodulatory drug treatment in multiple myeloma patients.
Fiche publication
Date publication
novembre 2020
Journal
European journal of cancer care
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CAILLOT Denis, Dr CHRETIEN Marie-Lorraine
Tous les auteurs :
Cransac A, Aho S, Cosme E, Chretien ML, Favennec C, Schreder L, Boutet M, Gueneau P, Giroud M, Caillot D, Boulin M
Lien Pubmed
Résumé
Immunomodulatory drugs (IMIDs: thalidomide, lenalidomide and pomalidomide) are widely used in patients with multiple myeloma (MM). The aim of our study was to validate a questionnaire to evaluate the self-capacity of MM patients to manage IMID treatment including side effects.
Mots clés
adherence, immunomodulatory drugs, multiple myeloma, questionnaire, self-management, side effects
Référence
Eur J Cancer Care (Engl). 2020 Nov 6;:e13356